1) 非営利機関以外の利用者は事前に<a href= 'http://ips-cell.net/j/index.php' target="_blank">iPSアカデミアジャパン株式会社 </a>から確認書を得ること。2) 利用者は、事前に承諾者から承諾を得ること。3) 先ずは、<a href="mailto:cellips.brc@riken.jp?subject=Disease specific iPS cell line 問い合わせ&">理研細胞バンク</a>にお問い合わせください 。
1) In relation to the for-profit organizations, please contact <a href= 'http://ips-cell.net/e/index.php' target="_blank">iPS Academia Japan, Inc.</a>, prior to the utilization of iPS cells. 2) The RECIPIENT agrees to obtain the prior written approval of the distribution from the APPROVER. 3) Contact Us : <a href="mailto:cellips.brc@riken.jp?subject=Disease specific iPS cell line&">RIKEN Cell Bank</a>
HPS0119
Disease specific iPS cell line derived from a patient : Chronic infantile neurological cutaneous and articular (CINCA) syndrome (somatic mosaicism). HPS0120 was derived from the same patient. <a href='http://cell.brc.riken.jp/en/wp-content/uploads/pdf/hps/HPS0119.pdf' target="_blank">Application consideration</a>. Order Form (C-0042, C-0057, C-0007 or C-0007p).
疾患特異的iPS細胞株。慢性乳児神経皮膚関節炎症候群（CINCA症候群）患者由来。HPS0120と同一人由来。レトロウイルスベクターにより4因子（Oct3/4, Sox2, Klf4, c-Myc）を導入して樹立。<a href='http://cell.brc.riken.jp/ja/manual/vitrification' target="_blank">ガラス化法（Vitrification法）</a>保存。<a href='http://cell.brc.riken.jp/ja/wp-content/uploads/pdf/hps/HPS0119.pdf' target="_blank">培養開始にあたっての注意。
疾患特異的iPS細胞株。慢性乳児神経皮膚関節炎症候群（CINCA症候群）患者由来。HPS0120と同一人由来。レトロウイルスベクターにより4因子（Oct3/4, Sox2, Klf4, c-Myc）を導入して樹立。<a href='https://cell.brc.riken.jp/ja/manual/vitrification' target="_blank">ガラス化法（Vitrification法）</a>保存。<a href='https://cell.brc.riken.jp/ja/wp-content/uploads/pdf/hps/HPS0119.pdf' target="_blank">培養開始にあたっての注意。
CiRA188Ai-M1
<a href="http://www.cira.kyoto-u.ac.jp/" target="_blank">http://www.cira.kyoto-u.ac.jp/</a>
Disease specific iPS cell line derived from a patient : Chronic infantile neurological cutaneous and articular (CINCA) syndrome (somatic mosaicism). HPS0120 was derived from the same patient. <a href="https://cell.brc.riken.jp/en/wp-content/uploads/pdf/hps/HPS0119.pdf" target="_blank" rel="noreferrer">Application consideration</a>.